Shots:

• The US FDA has approved the 420 mg multi-dose vial of Ontruzant (trastuzumab-dttb)- a biosimilar referencing Herceptin (trastuzumab) and will be marketed & distributed by Merck in the US
• On Feb 05- 2020- Merck has announced the spin-off its biosimilar business and will continue to support the commercialization of Ontruzant until the spinoff- which is anticipated to be held in H1’21
• Ontruzant (150 mg- single-dose vial) is an approved therapy for HER2-overexpressing BC- mBC and mGC or gastroesophageal junction adenocarcinoma in patients with prior treatment for metastatic disease

Click here ­to­ read full press release/ article 

 Ref: Samsung Bioepis | Image: Samsung Bioepis